NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control
NI-3201 is a novel PD-L1xCD28 bispecific antibody (bsAb) designed to enhance T cell activity and boost anti-tumor function. By combining PD-L1 blockade with conditional CD28 costimulation, NI-3201 offers a dual mechanism of action that promotes robust T cell responses while maintaining safety. This approach has demonstrated significant promise, including:
✅ Enhanced T cell effector function in preclinical models
✅ Tumor regression and immunological memory induction
✅ Synergistic effects with T cell engagers
✅ Favorable tolerability and pharmacokinetics in non-human primates
The potential of NI-3201 to improve outcomes for patients resistant to current immunotherapies is compelling, and we’re excited to take this innovative therapy forward in the clinic.
We're thrilled to share that the NI-3201 program is on track to enter clinical trials by mid-2025.
You can access the full manuscript here.
